The FDA’s Shifting Stance on Expedited Drug Approval: A Biotech Turning Point? The recent snag between Stoke Therapeutics and the FDA regarding accelerated approval for zorevunersen, a potential treatment for Dravet syndrome, isn’t an isolated incident. It signals a potentially significant shift in how the agency evaluates novel therapies, particularly those utilizing innovative approaches like … Read more
Alnylam’s Bold Vision: Gene Silencing and the Future of Biotech Alnylam, a pioneer in RNA interference (RNAi) therapeutics, recently unveiled its “Alnylam 2030” plan, signaling a continued commitment to innovation and ambitious growth. While recent quarterly sales of its flagship drug, Amvuttra, slightly missed expectations, the company’s long-term outlook remains remarkably optimistic. This isn’t just … Read more
The Enduring Legacy of David Mitchell: Charting the Future of Drug Pricing Reform A decade ago, the conversation around prescription drug pricing felt…stuck. Outrage simmered, but lacked direction. The story of David Mitchell, who recently passed away, wasn’t just about fighting for his own life against multiple myeloma; it was about igniting a movement. His … Read more
The Price of Secrecy: How Drug Pricing Obscurity Could Shape Healthcare’s Future The recent decision by the Trump administration to delay the public disclosure of net drug prices – the actual amount paid after rebates – isn’t a standalone event. It’s a symptom of a deeper struggle for transparency in the U.S. healthcare system, and … Read more
The Pill Revolution: How Oral Weight Loss Drugs Are Reshaping the Obesity Treatment Landscape For years, the fight against obesity has largely relied on lifestyle changes and injectable medications. Now, a new era is dawning with the FDA’s recent approval of oral Wegovy, Novo Nordisk’s pill form of the blockbuster weight loss drug. This isn’t … Read more
Why Oral Antibiotics Are the Next Frontier in Gonorrhea Treatment For decades the world has relied on a single injectable drug—ceftriaxone—to treat uncomplicated urogenital gonorrhea. The rise of multidrug‑resistant Neisseria gonorrhoeae has forced health authorities to search for alternatives. The recent FDA approvals of Zoliflodacin (Nuzolvence) and Gepotidacin (Blujepa) represent a watershed moment: the first … Read more
Why $16 B in Medicare Reconciliation Payments Matters Each year Medicare reconciles the cost gap between what insurers projected for Part D drug plans and what they actually spent. When costs exceed projections, the federal government pours money into insurers to keep the market stable. In the most recent cycle, that infusion topped a record $16 billion—a clear … Read more
Why Non‑Injectable Peptide Delivery Is Gaining Traction Therapeutic peptides have long been hampered by the need for injections, which limit patient compliance and increase clinic overhead. A new class of oral dissolving strips is turning that paradigm on its head by delivering peptides directly through the oral mucosa. The result is higher bioavailability, painless administration, … Read more
Retatrutide Sets a New Bar for Obesity Therapy Eli Lilly’s next‑generation obesity drug, retatrutide, just delivered the most dramatic weight‑loss results ever recorded in a late‑stage trial. Patients on the highest dose shed an average 23.7 % of body weight after 68 weeks, and a best‑case analysis shows a staggering 28.7 % loss. The same study also reported a … Read more
The Biosecure Act: A Turning Point for US-China Biotech Relations? Congress is on the verge of passing the Biosecure Act, a piece of legislation that’s been significantly reshaped over the past two years. Initially intended as a much stricter curb on Chinese biotech firms, the current version aims to restrict dealings between US pharmaceutical and … Read more